Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 49.e15-49.e21

  Nishikawa, Masatomo ^a   Miyake, Hideaki ^a   Harada, Ken ichi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

4E BP1; MTOR pathway; Prognosis; Radical nephrectomy; Renal cell carcinoma

Indexed keywords

C REACTIVE PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

4E-BP1; MTOR PATHWAY; PROGNOSIS; RADICAL NEPHRECTOMY; RENAL CELL CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEPHRECTOMY; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHOPROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84890791290     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.07.014     Document Type: Article

References (27)

1. Rini B.I., Rathmell W.K., Godley P. Renal cell carcinoma. Curr Opin Oncol 2008, 20:300-306.
2. Bellmunt J., Montagut C., Albiol S., Carles J., Maroto P., Orsola A. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007, 99:274-280.
3. Chowdhury S., Larkin J.M., Gore M.E. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008, 44:2152-2162.
4. Mahajan K., Mahajan N.P., PI3K-independent A.K. T activation in cancers: a treasure trove for novel therapeutics. J Cell Physiol 2012, 227:3178-3184.
5. Fasolo A., Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des 2012, 18:2766-2777.
6. Sheppard K., Kinross K.M., Solomon B., Pearson R.B., Phillips W.A. Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog 2012, 17:69-95.
7. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
8. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., Torbenson M. mTOR and p70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10:8421-8425.
9. Guanzhen Y., Jiejun W., Keping X., et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 2009, 15:1821-1829.
10. Bose S., Chandran S., Mirocha J.M., Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245.
11. Oh M.H., Lee H.J., Yoo S.B., et al. Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 2012, 460:601-609.
12. Sun C.H., Chang Y.H., Pan C.C. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011, 58:1054-1063.
13. Schultz L., Chaux A., Albadine R., et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Am J Surg Pathol 2011, 35:1549-1556.
14. Pantuck A.J., Seligson D.B., Klatte T., et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
15. Darwish O.M., Kapur P., Youssef R.F., et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013, 81:581-586.
16. Kurahashi T., Miyake H., Hara I., Fujisawa M. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol 2007, 177:757-761.
17. Abou Youssif T., Fahmy M.A., Koumakpayi I.H., et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011, 117:290-300.
18. Zhou X., Tan M., Stone Hawthorne V., et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788.
19. Dai B., Kong Y.Y., Ye D.W., Ma C.G., Zhou X., Yao X.D. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2012, 104:1009-1016.
20. Méjean A., Oudard S., Thiounn N. Prognostic factors of renal cell carcinoma. J Urol 2003, 169:821-827.
21. Tunuguntla H.S., Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008, 179:2096-2102.
22. Husseinzadeh H.D., Garcia J.A. Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma. Curr Clin Pharmacol 2011, 6:214-221.
23. Jagdev S.P., Gregory W., Vasudev N.S., et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer 2010, 103:1649-1656.
24. Castellvi J., Garcia A., Rojo F., et al. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 2006, 107:1801-1811.
25. Castellvi J., Garcia A., Ruiz-Marcellan C., et al. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol 2009, 40:1413-1426.
26. Yeh C.J., Chuang W.Y., Chao Y.K., et al. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma. Virchows Arch 2011, 458:171-178.
27. Armengol G., Rojo F., Castellvi J., et al. 4E-binding protein 1: a key molecular ''funnel factor'' in human cancer with clinical implications. Cancer Res 2007, 67:7551-7555.